CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Innovative Clinical Solutions Ltd. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Innovative Clinical Solutions Ltd.
SUITE 400, 10 DORRANCE ST
Phone: (401) 831-6755p:401 831-6755 PROVIDENCE, RI  02903  United States

This company ceased filing statements with the SEC on 2/14/2003.
This company is no longer actively traded on any major stock exchange.

Business Summary
Innovative Clinical Solutions, Ltd. (ICSL) is engaged in investigative clinical site management, including outcomes research, and single-specialty provider network management. On January 25, 2002, ICSL announced that it had determined to discontinue operations of its network management business. On February 7, 2002, ICSL completed a transaction with Comprehensive Neuroscience, Inc. (CNS), in which its wholly owned subsidiary, Clinical Studies, Ltd., which operates ICSL's investigative clinical site management and outcomes research, became a wholly owned subsidiary of CNS, a clinical knowledge company focused on the development, evaluation and appropriate use of drugs used to treat neuropsychiatric illnesses. Upon consummation of the Merger on February 7, 2002, ICSL owned 42% of CNS. The combined new CNS has three divisions: Clinical Trials, Medical Information Technologies and Drug Discovery.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
1/31/20021/31/2002-YesYes--

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Michael T.Heffernan 49 2/7/2002 4/1/1999
Chief Operating Officer for Network Management JohnWardle 53 4/1/1999 4/1/1999
Director GeraldHellerman 77 5/16/2002 5/16/2002
Director Yang T.Lie 42 9/1/2000 9/1/2000
Director David M.Livingston 66 1/1/1996 1/1/1996

Business Names
Business Name
CONTINUUM CARE CORP
PHYMATRIX CORP

General Information
Stock Exchange: OTC
Federal Tax Id: 650617076


Copyright © 2021 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 5, 2021